Lakefront Biotherapeutics NV revenue

Lakefront Biotherapeutics NV's revenue was $1.26bn in fiscal 2025, up 321.6% on the year before. Since fiscal 2015 ($43.9m) it has grown at a compound 39.9% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Lakefront Biotherapeutics NV: revenue history, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	44	143	144	329	935	545	277	254	259	298	1,258
Growth on the year before	—	+226.7%	+0.1%	+129.3%	+183.8%	−41.6%	−49.2%	−8.3%	+2.0%	+15.0%	+321.6%
Gross profit	—	—	—	—	—	—	275	241	—	261	1,224
Gross margin	—	—	—	—	—	—	99.3%	95.0%	—	87.4%	97.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Lakefront Biotherapeutics NV	$1.26bn	321.6%	—
Madrigal Pharmaceuticals, Inc.	$1.28bn	149.0%	—
PTC Therapeutics, Inc.	$1.16bn	-35.1%	13.1%
Acadia Pharmaceuticals Inc	$1.14bn	11.8%	27.4%
Insmed Inc	$1.52bn	240.0%	75.6%
Legend Biotech Corp	$1.03bn	64.0%	—

Compare with peers

Head to head: LKFT vs MDGL LKFT vs PTCT ACAD vs LKFT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lakefront Biotherapeutics NV's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lakefront Biotherapeutics NV.